Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 99

1.

Efficacy and safety of keratinocyte growth factor (palifermin) for prevention of oral mucositis in TBI-based allogeneic hematopoietic stem cell transplantation.

Schmidt V, Niederwieser D, Schenk T, Behre G, Klink A, Pfrepper C, Hinke A, Beelen DW, Junghanss C, Uharek L, Krüger WH, Hochhaus A, Sayer HG; East German Study Group for Hematology and Oncology (OSHO).

Bone Marrow Transplant. 2018 Mar 15. doi: 10.1038/s41409-018-0135-3. [Epub ahead of print] No abstract available.

PMID:
29545592
2.

Trastuzumab without chemotherapy in the adjuvant treatment of breast cancer: subgroup results from a large observational study.

Dall P, Koch T, Göhler T, Selbach J, Ammon A, Eggert J, Gazawi N, Rezek D, Wischnik A, Hielscher C, Schleif N, Cirrincione U, Hinke A, Feisel-Schwickardi G.

BMC Cancer. 2018 Jan 8;18(1):51. doi: 10.1186/s12885-017-3857-5.

3.

AIO LQ-0110: a randomized phase II trial comparing oral doxycycline versus local administration of erythromycin as preemptive treatment strategies of panitumumab-mediated skin toxicity in patients with metastatic colorectal cancer.

Kripp M, Prasnikar N, Vehling-Kaiser U, Quidde J, Al-Batran SE, Stein A, Neben K, Hannig CV, Tessen HW, Trarbach T, Hinke A, Hofheinz RD.

Oncotarget. 2017 Sep 23;8(62):105061-105071. doi: 10.18632/oncotarget.21249. eCollection 2017 Dec 1.

4.

Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials.

Goey KKH, Elias SG, Hinke A, van Oijen MGH, Punt CJA, Hegewisch-Becker S, Arnold D, Koopman M.

Br J Cancer. 2017 Dec 5;117(12):1768-1776. doi: 10.1038/bjc.2017.382. Epub 2017 Nov 9.

PMID:
29123255
5.

Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial.

Möbus V, Jackisch C, Lück HJ, du Bois A, Thomssen C, Kuhn W, Nitz U, Schneeweiss A, Huober J, Harbeck N, von Minckwitz G, Runnebaum IB, Hinke A, Konecny GE, Untch M, Kurbacher C; AGO Breast Study Group (AGO-B).

Ann Oncol. 2018 Jan 1;29(1):178-185. doi: 10.1093/annonc/mdx690.

PMID:
29069370
6.

Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a systematic review and meta-analysis.

Jordan K, Blättermann L, Hinke A, Müller-Tidow C, Jahn F.

Support Care Cancer. 2018 Jan;26(1):21-32. doi: 10.1007/s00520-017-3857-7. Epub 2017 Aug 31. Review.

PMID:
28861627
7.

Primary metastatic breast cancer in the era of targeted therapy - Prognostic impact and the role of breast tumour surgery.

Barinoff J, Schmidt M, Schneeweiss A, Schoenegg W, Thill M, Keitel S, Lattrich CR, Hinke A, Kutscheidt A, Jackisch C.

Eur J Cancer. 2017 Sep;83:116-124. doi: 10.1016/j.ejca.2017.06.002. Epub 2017 Jul 20.

PMID:
28735068
8.

Dose-escalation study evaluating pegylated interferon alpha-2a in patients with cutaneous T-cell lymphoma.

Schiller M, Tsianakas A, Sterry W, Dummer R, Hinke A, Nashan D, Stadler R.

J Eur Acad Dermatol Venereol. 2017 Nov;31(11):1841-1847. doi: 10.1111/jdv.14366. Epub 2017 Jul 20.

PMID:
28557110
9.

Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany.

Dall P, Koch T, Göhler T, Selbach J, Ammon A, Eggert J, Gazawi N, Rezek D, Wischnik A, Hielscher C, Keitel S, Cirrincione U, Hinke A, Feisel-Schwickardi G.

Oncologist. 2017 Feb;22(2):131-138. doi: 10.1634/theoncologist.2016-0193. Epub 2017 Feb 7.

10.

Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial.

Straka C, Liebisch P, Salwender H, Hennemann B, Metzner B, Knop S, Adler-Reichel S, Gerecke C, Wandt H, Bentz M, Bruemmendorf TH, Hentrich M, Pfreundschuh M, Wolf HH, Sezer O, Bargou R, Jung W, Trümper L, Hertenstein B, Heidemann E, Bernhard H, Lang N, Frickhofen N, Hebart H, Schmidmaier R, Sandermann A, Dechow T, Reichle A, Schnabel B, Schäfer-Eckart K, Langer C, Gramatzki M, Hinke A, Emmerich B, Einsele H.

Haematologica. 2016 Nov;101(11):1398-1406. Epub 2016 Aug 4.

11.

Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial.

Quidde J, Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, Lange T, Dietrich G, Stoehlmacher J, Reinacher A, Tannapfel A, Trarbach T, Marschner N, Schmoll HJ, Hinke A, Al-Batran SE, Arnold D.

Ann Oncol. 2016 Dec;27(12):2203-2210. doi: 10.1093/annonc/mdw425. Epub 2016 Oct 17.

PMID:
27753609
12.

Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study - AIO SUP-0108.

Jordan K, Luetkens T, Gog C, Killing B, Arnold D, Hinke A, Stahl M, Freier W, Rüssel J, Atanackovic D, Hegewisch-Becker S.

Eur J Cancer. 2016 Aug;63:127-34. doi: 10.1016/j.ejca.2016.05.004. Epub 2016 Jun 15.

PMID:
27314448
13.

Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer--results from a non-interventional observation study.

Stein A, Quidde J, Schröder JK, Göhler T, Tschechne B, Valdix AR, Höffkes HG, Schirrmacher-Memmel S, Wohlfarth T, Hinke A, Engelen A, Arnold D.

BMC Cancer. 2016 Feb 10;16:82. doi: 10.1186/s12885-016-2113-8.

14.

Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.

Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, Niederle N, Losem C, Boeck HP, Weidmann E, von Gruenhagen U, Mueller L, Sandherr M, Hahn L, Vereshchagina J, Kauff F, Blau W, Hinke A, Barth J; Study Group Indolent Lymphomas.

Lancet Oncol. 2016 Jan;17(1):57-66. doi: 10.1016/S1470-2045(15)00447-7. Epub 2015 Dec 5. Erratum in: Lancet Oncol. 2016 Jan;17(1):e6.

PMID:
26655425
15.

CoCStom trial: study protocol for a randomised trial comparing completeness of adjuvant chemotherapy after early versus late diverting stoma closure in low anterior resection for rectal cancer.

Sandra-Petrescu F, Herrle F, Hinke A, Rossion I, Suelberg H, Post S, Hofheinz RD, Kienle P.

BMC Cancer. 2015 Nov 21;15:923. doi: 10.1186/s12885-015-1838-0.

16.

Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings-a meta-analysis.

Jordan K, Warr DG, Hinke A, Sun L, Hesketh PJ.

Support Care Cancer. 2016 May;24(5):1941-1954. doi: 10.1007/s00520-015-2990-4. Epub 2015 Oct 17.

PMID:
26476625
17.

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.

Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, Al-Batran SE, Lange T, Dietrich G, Stoehlmacher J, Tannapfel A, Reinacher-Schick A, Quidde J, Trarbach T, Hinke A, Schmoll HJ, Arnold D.

Lancet Oncol. 2015 Oct;16(13):1355-69. doi: 10.1016/S1470-2045(15)00042-X. Epub 2015 Sep 8. Erratum in: Lancet Oncol. 2015 Dec;16(16):e589.

PMID:
26361971
18.

Trastuzumab in the treatment of elderly patients with early breast cancer: Results from an observational study in Germany.

Dall P, Lenzen G, Göhler T, Lerchenmüller C, Feisel-Schwickardi G, Koch T, Eggert J, Heilmann V, Schindler C, Wilke J, Tesch H, Selbach J, Wohlfarth T, Eustermann H, Hinke A.

J Geriatr Oncol. 2015 Nov;6(6):462-9. doi: 10.1016/j.jgo.2015.06.003. Epub 2015 Sep 2.

19.

The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax).

Al-Batran SE, Hozaeel W, Tauchert FK, Hofheinz RD, Hinke A, Windemuth-Kieselbach C, Hübner A, Burmester M, Koenigsmann M, Wiegand J, Zur Hausen G, Linsse B, Kuhl R, Pauligk C; Arbeitsgemeinschaft Internistische Onkologie (AIO).

Ann Oncol. 2015 Jun;26(6):1244-8. doi: 10.1093/annonc/mdv129. Epub 2015 Mar 9.

PMID:
25755108
20.

Trastuzumab in advanced breast cancer--a decade of experience in Germany.

Jackisch C, Schoenegg W, Reichert D, Welslau M, Selbach J, Harich HD, Tesch H, Wohlfarth T, Eustermann H, Hinke A.

BMC Cancer. 2014 Dec 8;14:924. doi: 10.1186/1471-2407-14-924.

Supplemental Content

Support Center